ARCHIVES

NCI Issues Statement On Endostatin Research

This article is from The Cancer Letter archive.

Vol. 25 No. 37 | October 1, 1999

Download PDF Visit The Full Archive

Related Articles

Xeloda + Oxaliplatin Compares To FOLFOX-4 In First Line

January 30, 2009

$5 Million Lift Raises Payline From 180 to 185

May 21, 1982

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

NCI T BE More Flexible In Funding RFAs Above Paylines

June 23, 1989

Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients

November 30, 2012

FCRC Committee Limited To Review Of Basic Science

November 26, 1976